TMDX | TransMedics Group, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	N/A - N/A
52 Week Range	N/A - N/A
Beta	2.29
Implied Volatility	87.36%
IV Rank	6.36%
Day's Volume	N/A
Average Volume	N/A
Shares Outstanding	N/A
Market Cap	N/A
Sector	Healthcare
Industry	Medical - Devices
IPO Date	2019-05-02

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	584
Country	USA
Website	TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

TMDX's peers: ALGN, SMLR, DCTH, INMD, INSP, MASI, NVCR, PAVM, PEN, PODD, RCEL, TELA, NARI, SILK, LUNG, OFIX, CVRX, NPCE, SWAV, XAIR

*Chart delayed

Analyzing fundamentals for TMDX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is weak. For more detailed analysis please see TMDX Fundamentals page.

Watching at TMDX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TMDX Technicals page.